There has been considerable criticism of SSRI antidepressants like Paxil for increasing suicide risks, especially in teenagers, but needless to say Big Pharma hasn’t wanted to hear it. Now leading drug company GlaxoSmithKline (GSK) has been caught with its pants down, so to speak, as reported by Reuters via Scientific American:
… Read the rest
A medical journal criticised British drugmaker GlaxoSmithKline on Thursday for delaying access to key data from a trial of its antidepressant paroxetine (Seroxat, Paxil) that would have shown earlier that it is neither safe nor effective in adolescents.
The widely used medicine is linked to an increased risk of suicide in young people and has carried a Food and Drug Administration (FDA) “black box warning” advising against its use in adolescents since 2004.
Britain’s Medicines and Healthcare Products Regulatory Agency recommended in 2003 that antidepressants like paroxetine should not be used in children or adolescents, and European regulators followed suit in 2005.